Dashboard
Manage Tickers

SLDB Solid Biosciences Inc.

Nasdaq solidbio.com


$ 5.05 $ -0.15 (-2.8 %)    

Monday, 03-Nov-2025 19:38:04 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 5.2
$ 5.35
$ 4.50 x 80
$ 5.59 x 2
$ 5.09 - $ 5.48
$ 2.41 - $ 7.37
1,736,795
na
405.13M
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-06-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-13-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 04-27-2022 03-31-2022 10-Q
16 03-14-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-13-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

solid-biosciences-reports-interim-data-from-inspire-duchenne-trial-showing-strong-microdystrophin-expression-and-muscle-biomarker-improvements
Solid Biosciences Reports Interim Data Fro...
11/03/2025 21:26:30

INSPIRE DUCHENNE – Interim Clinical Data UpdateINSPIRE DUCHENNE is a Phase 1/2 first-in-human, open-label, single-dose, multice...

solid-biosciences-q3-eps-048-misses-043-estimate
Solid Biosciences Q3 EPS $(0.48) Misses $(...
11/03/2025 21:23:41

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $...

solid-biosciences-announces-non-exclusive-licensing-agreement--with-kinea-bio-granting-kinea-license-to-utilize-aav-slb101-as-the-delivery-backbone-for-kna-155
Solid Biosciences Announces Non-Exclusive ...
09/23/2025 12:10:16

chardan-capital-maintains-buy-on-solid-biosciences-maintains-15-price-target
Chardan Capital Maintains Buy on Solid Bio...
08/14/2025 16:18:47

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $15 price target.

jp-morgan-maintains-overweight-on-solid-biosciences-lowers-price-target-to-13
JP Morgan Maintains Overweight on Solid Bi...
08/14/2025 15:49:17

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $...

wedbush-maintains-outperform-on-solid-biosciences-lowers-price-target-to-14
Wedbush Maintains Outperform on Solid Bios...
08/13/2025 14:44:08

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17...

solid-biosciences-q2-eps-042-beats-053-estimate
Solid Biosciences Q2 EPS $(0.42) Beats $(0...
08/12/2025 20:36:14

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0...

solid-biosciences-receives-fda-fast-track-designation-for-sgt-501-gene-therapy-for-catecholaminergic-polymorphic-ventricular-tachycardia
Solid Biosciences Receives FDA Fast Track ...
07/23/2025 12:01:54

solid-biosciences-receives-fda-ind-and-health-canada-cta-approval-for-first-in-class-cardiac-gene-therapy-to-treat-catecholaminergic-polymorphic-ventricular-tachycardia
Solid Biosciences Receives FDA IND And Hea...
07/08/2025 20:08:11

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -- SGT-...

citigroup-initiates-coverage-on-solid-biosciences-with-buy-rating-announces-price-target-of-14
Citigroup Initiates Coverage On Solid Bios...
06/26/2025 11:50:54

Citigroup analyst Yigal Nochomovitz initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Pr...

analyst-downgrades-sarepta-as-elevidys-safety-clouds-future-demand
Analyst Downgrades Sarepta As Elevidys Saf...
06/20/2025 18:10:20

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenu...

hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Soli...
06/17/2025 11:09:54

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $20 price target.

sarepta-therapeutics-kulr-technology-group-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Sarepta Therapeutics, KULR Technology Grou...
06/16/2025 12:38:15

why-incyte-shares-are-trading-higher-by-around-10-here-are-20-stocks-moving-premarket
Why Incyte Shares Are Trading Higher By Ar...
06/16/2025 10:00:21

jmp-securities-reiterates-market-outperform-on-solid-biosciences-maintains-15-price-target
JMP Securities Reiterates Market Outperfor...
06/06/2025 14:13:15

JMP Securities analyst Silvan Tuerkcan reiterates Solid Biosciences (NASDAQ:SLDB) with a Market Outperform and maintains $15...

cantor-fitzgerald-assumes-solid-biosciences-at-overweight-announces-price-target-of-16
Cantor Fitzgerald Assumes Solid Bioscience...
05/22/2025 14:30:17

Cantor Fitzgerald analyst Kristen Kluska assumes Solid Biosciences (NASDAQ:SLDB) with a Overweight rating and announces Pric...

chardan-capital-maintains-buy-on-solid-biosciences-lowers-price-target-to-15
Chardan Capital Maintains Buy on Solid Bio...
05/19/2025 12:21:18

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and lowers the price target fro...

piper-sandler-maintains-overweight-on-solid-biosciences-lowers-price-target-to-17
Piper Sandler Maintains Overweight on Soli...
05/16/2025 16:17:12

Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target fro...

wedbush-maintains-outperform-on-solid-biosciences-lowers-price-target-to-17
Wedbush Maintains Outperform on Solid Bios...
05/16/2025 14:01:16

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $18...

barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-10
Barclays Maintains Overweight on Solid Bio...
05/16/2025 13:57:56

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $15 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION